Generic DAA therapy safely, effectively treats pediatric HCV

Source/Revelations

Published by:

Source:

El-Sayed MH, et al. OS-2306. Presented at: the International Liver Congress; June 23-26 (virtual meeting).

disclosures:
El-Sayed reports that she has a relationship with commercial entities that could be seen as having a connection to her presentation.

ADD TOPIC TO EMAIL ALERTS

Receive an email when new articles are posted

Enter your e-mail address to receive an e-mail when there are new articles on . ” data-action = “subscribe” > Subscribe

We were unable to process your request. Try again later. If this problem persists, please contact customerservice@slackinc.com.

Back to Healio

Administration of direct-acting antivirals treated children with hepatitis C safely and effectively, according to a presentation at the International Liver Congress.

“The worldwide prevalence of hepatitis C in children is clearly demonstrated in this pilot study from the Center for Disease Analysis, where the viremic prevalence of the pediatric population in 249 countries was estimated to be 0.13%, which corresponds to approximately 3.26 million infected people. children,” manual hamdy El-Sayed, MD, PhD, said in the presentation.

El-Sayed and colleagues studied the efficacy of the Egyptian Liver Care Society (ELCS) ongoing C-free Child Project phase 4 administration of oral DAAs. According to the abstract, between March 2019 and December 2020, the multicenter program enrolled 535 children with chronic HCV and weighed more than 35 kg in 7 centers in Egypt.

The ELCS treated patients with generic oral DAAs daily for 12 weeks. Full treatment included baseline and follow-ups at 4, 8, and 12 weeks and on evaluation of sustained virologic response; echoes; prevention and personal care items during therapy and in SVR assessment after 24 weeks; Fibroscan (Echosens) and medication provision. The program trained medical staff, delivered health workshops to children and their families and fully equipped all centers.

During the COVID-19 pandemic, the ELCS held virtual follow-ups and workshops, distributed medication for 12 weeks and provided protective and decontamination measures.

Of all enrolled children, 264 have completed the SVR evaluation to date, with a median age of 16 years (range 11.5-17.5 years; M/F 1.4/1). On an intention-to-treat basis, SVR presented in 249 (94%) of patients evaluated, but the SVR per protocol was 100%. El-Sayed said this demonstrated the high efficacy and safety of DAA therapy for HCV in children, with only minor side effects such as headache, dizziness and loss of appetite.

The most common risk factors identified included multiple injections (84%), dental procedures (50%) and informal medical service (50%). Ninety-seven children (37%) had mothers with an HCV infection. Heart disease, haemophilia, lymphoma and thalassemia affected 12 children; 51 children were cancer survivors, representing 19% of those who completed the SVR assessment.

“Children and adolescents are a marginalized population that is often neglected in policies and guidelines,” El-Sayed said. “The NGOs can play a major role in supporting the pediatric and indeed the high-risk populations, by providing models of service and removing stigma and discrimination.”

ADD TOPIC TO EMAIL ALERTS

Receive an email when new articles are posted

Enter your email address to receive an email when there are new articles on . ” data-action = “subscribe” > Subscribe

We were unable to process your request. Try again later. If this problem persists, please contact customerservice@slackinc.com.

Back to Healio

International Delivery Congress

Comments are closed.